Amphastar Pharmaceuticals Inc AMPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AMPH is a good fit for your portfolio.
News
-
BetterInvesting™ Magazine Update on Amphastar Pharmaceuticals Inc. and Medtronic PLC
-
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
-
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
-
Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
-
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference
-
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024
-
Amphastar Pharmaceuticals Shares Down 9% After Private Notes Offering
Trading Information
- Previous Close Price
- $37.75
- Day Range
- $37.00–38.45
- 52-Week Range
- $37.00–67.66
- Bid/Ask
- $36.57 / $39.75
- Market Cap
- $1.83 Bil
- Volume/Avg
- 896 / 355,358
Key Statistics
- Price/Earnings (Normalized)
- 10.05
- Price/Sales
- 2.94
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 2.74%
Company Profile
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,761
- Website
- https://www.amphastar.com
Comparables
Valuation
|
Metric
|
AMPH
|
LFCR
|
PROC
|
|---|---|---|---|
Price/Earnings (Normalized) | 10.05 | — | 82.13 |
Price/Book Value | 2.71 | — | 7.16 |
Price/Sales | 2.94 | — | 0.62 |
Price/Cash Flow | 8.66 | — | 5.55 |
Price/Earnings
AMPH
LFCR
PROC
Financial Strength
|
Metric
|
AMPH
|
LFCR
|
PROC
|
|---|---|---|---|
Quick Ratio | 1.68 | 1.22 | 0.97 |
Current Ratio | 2.18 | 2.39 | 1.47 |
Interest Coverage | 6.05 | −2.63 | 2.77 |
Quick Ratio
AMPH
LFCR
PROC
Profitability
|
Metric
|
AMPH
|
LFCR
|
PROC
|
|---|---|---|---|
Return on Assets (Normalized) | 14.66% | −8.68% | 0.21% |
Return on Equity (Normalized) | 32.66% | −39.95% | 7.45% |
Return on Invested Capital (Normalized) | 19.89% | −4.61% | 10.39% |
Return on Assets
AMPH
LFCR
PROC
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Dtzgnkvqv | Tcfz | $80.0 Bil | |||
| Merck KGaA ADR
MKKGY
| Tkcjxxkcj | Bqwxxdn | $71.1 Bil | |||
| Haleon PLC ADR
HLN
| Pwdtcbdhv | Hmlt | $38.2 Bil | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Tdqsdvgcx | Ydpjn | $18.5 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Fdxbwwtt | Jygc | $13.0 Bil | |||
| Viatris Inc
VTRS
| Zqzxjnw | Jdrz | $12.6 Bil | |||
| Catalent Inc
CTLT
| Wypnhlxl | Ckgyclc | $10.3 Bil | |||
| Perrigo Co PLC
PRGO
| Cchxldsrz | Dbtxl | $3.5 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Jdmrrkqh | Rbxrgf | $3.4 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Fprmztlrq | Gwvx | $2.9 Bil |